Acinetobacter sp., particularly A. baumannii, is emerging bacterial pathogens that have become prevalent worldwide. A. baumannii is the second most common Gram-negative pathogen isolated from clinical samples after Pseudomonas aeruginosa. Multidrug-resistant Acinetobacter baumannii (MDRAB) is often associated with co-infection by other pathogenic organisms, which can make it challenging to determine its attributable mortality. In addition to antibiotic resistance, biofilm formation is another characteristic that contributes to the survival of A. baumannii in the presence of antibiotics and high stresses.A. baumannii has become a significant concern for healthcare systems worldwide because of its ability to rapidly develop antibiotic resistance. In recent years, it has been increasingly associated with hospital-acquired infections, especially in intensive care units (ICUs), where patients are at increased risk of developing infections due to their weakened immune system and invasive procedures. MDRAB infections are difficult to treat, and this problem is compounded by the ability of A. baumannii to form biofilms. Biofilms are complex communities of microorganisms embedded in a matrix of extracellular polymeric substances (EPS). The EPS matrix provides a protective environment for the microorganisms, making it difficult for antibiotics to penetrate and reach the bacterial cells. This mechanism of protection allows A. baumannii to survive in hostile environments and resist the effects of antibiotics and disinfectants.